Objectives: To determine the value of surgery for infective endocarditis (IE) in patients on hemodialysis by comparing the nature and invasiveness of endocarditis in hemodialysis and nonhemodialysis patients and their hospital and long-term outcomes, and identifying risk factors for time-related mortality after surgery.
Results: Staphylococcus aureus infection was more common in hemodialysis patients than in nonhemodialysis patients (42% vs 21%; P <.0001), but invasive disease was similar in the 2 groups (47%; P ¼ .3). Hospital mortality was 13% and 5-year survival was 20% for hemodialysis patients, 20% below that expected in a general hemodialysis population but 15% above that of hemodialysis patients treated nonsurgically for IE. For matched patients, hospital mortality was 13% for hemodialysis patients versus 5.1% for nonhemodialysis patients (P ¼ .05), and survival at 1 and 5 years was 56% versus 83% and 24% versus 59%, respectively (P < .004). Use of an arteriovenous graft for dialysis access (P ¼ .01) and preoperative placement of a pacemaker (P < .0001) were risk factors for late mortality in hemodialysis patients. For matched patients, freedom from reoperation was similar in the hemodialysis and nonhemodialysis groups (P >.9).
Conclusions: Intermediate-term survival after surgery for IE in hemodialysis patients is substantially worse than that in nonhemodialysis patients, but only slightly worse than that in the general hemodialysis population and substantially better than that in hemodialysis patients with IE treated nonsurgically, supporting continued surgical intervention for IE. (J Thorac Cardiovasc Surg 2017;154:61-70)
Survival of patients with infective endocarditis (IE ) on or not on hemodialysis (HD ).

Central Message
With a 5-year survival of 24%, surgery for infective endocarditis should be considered for patients on hemodialysis.
Perspective
Survival after surgery for infective endocarditis (IE) in patients receiving hemodialysis is substantially worse than for otherwise similar patients not receiving hemodialysis, but only somewhat worse than that for the general hemodialysis population and substantially better than that for hemodialysis patients with nonsurgically treated IE, supporting surgical intervention for IE in this high-risk population.
See Editorial Commentary page 71.
Vascular access exposes patients on hemodialysis to a persistent source of environmental pathogens at the entry site. Consequently, the incidence of infective endocarditis (IE) is 18 times higher in hemodialysis patients than in the general US population. 1 With more than 400,000 patients on hemodialysis in the US, the morbidity and mortality associated with IE in these patients is an important healthcare issue. 2 In reports published a decade ago, operative mortality after surgery for IE in these patients ranged from 24% to 73%, [3] [4] [5] and survival was recently reported to be as low as 25% at 3 years and 0% at 5 years. 6, 7 To evaluate the value of surgery for IE in patients on hemodialysis, we compared the nature and invasiveness of IE and the hospital and long-term outcomes in hemodialysis and nonhemodialysis patients, contrasted their survival with that of hemodialysis patients with IE not treated surgically, and identified risk factors for time-related mortality after surgery for IE.
PATIENTS AND METHODS Patients
From January 1997 to January 2013, 1413 patients underwent valve surgery for active IE at Cleveland Clinic. Of these, 144 (10%) were on chronic hemodialysis (more operated on in recent years; Figure 1 ), 8 (0.6%) were on chronic peritoneal dialysis (Appendix E1), and 28 (2%) were on dialysis for acute renal failure; 1233 (87%) were not on any form of dialysis (nonhemodialysis patients). The 28 patients on dialysis for acute renal failure are not considered in this report.
Study Design
Surgically treated chronic hemodialysis patients and nonhemodialysis patients are the 2 primary comparison groups in this study. In addition, for survival, 3 reference groups are considered: 29 hemodialysis patients with IE not treated surgically, diagnosed between July 2007 and January 2015; age-, race-, and sex-matched individuals in the general population 8 ; and hemodialysis patients in general (US Renal Data System, 2015 Annual Data Report Reference Tables; Reference Table I : Patient Survival). 9 
Data
All data used in this study were approved for use in research by the Cleveland Clinic's Institutional Review Board, with the requirement for patient consent waived. Preoperative, operative, and postoperative variables were retrieved from the prospectively maintained Cardiovascular Information Registry. Dialysis-related variables were collected through chart review, and infecting agents were adjudicated by infectious disease experts. Invasiveness data were available only for patients with IE who underwent surgery from 2002 onward (119 of 144 hemodialysis patients and 873 of 1233 nonhemodialysis patients), as described previously. 8, 10 Surgery for IE Surgical principles followed for patients with IE at Cleveland Clinic have been reported previously. 10, 11 A dedicated multispecialty team treats all patients presenting with IE. Preoperatively, all patients undergo brain imaging and many undergo imaging of the chest and abdomen to identify embolic complications. Surgery is advocated as soon as an indication is established, and the operation is expedited to avoid additional embolization and clinical deterioration. At surgery, radical debridement of all infected tissues and foreign material is followed by generous irrigation. Local antiseptics and antibiotics are used sparingly (Video 1).
The choice of replacement valve is based on pathology, overall complexity of the medical situation, life expectancy, and ability to comply with anticoagulation. Most hemodialysis patients received a tissue prosthesis to avoid anticoagulation (Table E1 ). In patients with aortic valve IE with annulus destruction and invasive disease, an allograft remains our preferred choice for aortic root reconstruction, which was used in 47% (38 of 81) of the hemodialysis patients undergoing aortic valve replacement. Severe mitral annular calcification is not uncommon in hemodialysis patients and is treated by limited calcium debridement and reconstruction as necessary to allow for an acceptable-sized valve. Whenever additional material is required for reconstruction, we prefer autologous pericardium.
Endpoints
Endpoints were in-hospital outcomes, with morbidities as defined in the Society of Thoracic Surgeons national database (available at http://www. sts.org/sites/default/files/documents/word/STSAdultCVDataSpecifications V2_73%20with%20correction.pdf), time-related mortality, and timerelated heart valve reoperation.
Systematic active follow-up was performed at 2 and 5 years and every 5 years thereafter, supplemented by a cross-sectional follow-up with a closing date of April 15, 2016 . To verify vital status, this systematic follow-up was supplemented with Social Security Death Master File data (accessed on October 27, 2011, with a closing date of April 27, 2011) and Ohio Death Registry data.
For hemodialysis patients, median follow-up for mortality was 1.4 years, with 25% of survivors followed for >5.6 years and 10% followed for >7.2 years; 355 patient-years of data were available for analysis. For matched nonhemodialysis patients, median follow-up for mortality was 4.3 years, with 25% of survivors followed for>8 years and 10% followed for >8.8 years; 448 patient-years of data were available for analysis. At 5 years, 12 of the 198 matched patients had been lost to follow-up for vital status, including 4 within 1 year and 8 within 3 to 5 years.
Median active follow-up for reoperation in the hemodialysis patients was 5.3 months, with 25% of survivors followed for >5.0 years and 10% followed for >5.5 years; 245 patient-years of data were available for analysis. For the matched nonhemodialysis patients, median active follow-up for reoperation was 2 years, with 25% of survivors followed for>6.0 years and 10% followed for>7 years; 279 patient-years of data were available for analysis. Among matched patients alive at 5 years, follow-up for reoperation was unavailable for 22; 14 were lost to follow-up within 1 year, 2 between 1 and 3 years, and 6 between 3 and 5 years.
Statistical Analysis
All analyses were performed using SAS version 9.1 (SAS Institute, Cary, NC).
Time-related mortality and reoperation. Time-related survival and freedom from reoperation were assessed nonparametrically using the Kaplan-Meier method 12 and parametrically using the multiphase nonproportional hazards model 13 (for additional details, see http://www.lerner. ccf.org/qhs/software/hazard/). Because death is a competing risk for reoperation, the likelihood of reoperation was also estimated using competingrisks methodology. 15, 16 For this, 1000 bootstrap datasets were generated, and automated stepwise variable selection was performed to identify variables with P .05. Results were aggregated, and variables appearing in 50% or more of the analyses were considered reliable risk factors.
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Comparison with nonhemodialysis patient outcomes.
Because patient characteristics differed between the hemodialysis and nonhemodialysis groups (Table 1) , in the spirit of a ''natural experiment'' we attempted to fairly compare outcomes using propensity matching. [14] [15] [16] Using multivariable logistic regression and bagging as described above, a parsimonious model of hemodialysis versus nonhemodialysis patients was developed based on the variables listed in Appendix E2, but without considering renal function (Table E2) . Then other variables representing groups of patient and procedure factors that might be related to unrecorded confounding factors were added (semisaturated model with 58 variables). A propensity score was calculated for each patient by solving the resulting propensity model. Using only the propensity score, hemodialysis patients were matched 1:1 to nonhemodialysis patients using a greedy-matching strategy 17 that yielded 99 well-matched patient pairs (69% of possible matches; Figure E1 ). Hemodialysis patients whose propensity scores deviated by >0.25 from those of nonhemodialysis patients were considered unmatched. The 45 unmatched hemodialysis patients were younger than the 99 matched hemodialysis patients (mean age, 50 AE 11 years vs 56 AE 12 years; P ¼ .002), and more of the unmatched hemodialysis patients were black (49% vs 22%; P ¼ .002) ( Figure E2 ).
Missing values.
In developing parsimonious and propensity models and identifying risk factors for death, 5-fold multiple imputation was used to impute missing values. 18 The tables indicate the number of values missing for each variable. For example, of the 58 variables used for the propensity score, 21 had no missing data, 19 had<5% missing data, 3 had 5% to 20% missing data, and 15 had >20% missing data. The pattern of missing data appeared arbitrarily, so ''missing at random'' was assumed.
Presentation
Continuous variables are summarized as mean AE standard deviation and as equivalent 15th, 50th (median), and 85th percentiles for skewed distributions; comparisons were made using the Wilcoxon rank-sum test. Categorical variables are summarized as frequencies and percentages, and comparisons were made using the c 2 test or Fisher's exact test when frequency was <5. Uncertainty is expressed by confidence limits equivalent to AE1 standard error (68%).
RESULTS
Characteristics of Hemodialysis and Nonhemodialysis Patients: Surgical Patients
Compared with nonhemodialysis patients undergoing surgery for IE, hemodialysis patients were younger, and more were black and had a history of diabetes, carotid disease, and hypertension ( Table 1) . As a group, hemodialysis patients had lower hematocrit, greater left ventricular mass index, lower bilirubin concentration, and lower cholesterol levels at the time of surgery.
Nature of the IE: Surgical Patients
The most common causative organism in both hemodialysis and nonhemodialysis surgical patients was Staphylococcus aureus, but a higher percentage of hemodialysis patients had this organism compared with nonhemodialysis patients (42% vs 21%; Table 2 ). Left-sided IE was present in 96% of hemodialysis patients and 95% of nonhemodialysis patients, and right-sided IE in 9% of hemodialysis patients and 11% of nonhemodialysis patients. Prosthetic valve endocarditis (PVE) was present in 19% of hemodialysis patients, compared with 36% of nonhemodialysis patients. Invasive disease was present in 47% of both hemodialysis and nonhemodialysis patients. There was no invasive disease in right-sided IE in either group.
Hospital Outcomes: Surgical Patients
Among the hemodialysis patients, overall hospital mortality was 13%; 4.2% had a stroke, 13% had septicemia, and 42% had respiratory failure (Table 3 ). In propensitymatched pairs, hospital mortality was higher (13% vs 5.0%) and intensive care unit and postoperative lengths of stay were longer in the hemodialysis patients compared with the nonhemodialysis patients, but other hospital outcomes were similar in the 2 groups.
Among hemodialysis patients with a catheter as dialysis access, the access was changed or the catheter replaced after surgery in 79% (46 of 58). Twelve patients had a preoperative pacemaker; it was removed in 6 patients, and epicardial leads were placed in 3.
Survival
Survival at 1, 3, 5, 7, and 10 years in hemodialysis patients after surgery for IE was 60%, 38%, 25%, 16%, and 8.4% (Figure 2, A) . These figures are substantially lower than in the age-, race-, and sex-matched US population, approximately 15 percentage points below the 76%, 54%, and 40% survival at 1, 3, and 5 years for the general hemodialysis population, 9 but higher than survival in hemodialysis patients with IE treated nonsurgically at our institution (outcomes reported in ''Nonsurgically Treated Hemodialysis Patients''). Instantaneous risk of death was highest early after surgery and gradually decreased over the first 12 months (Figure E3, A) . Thereafter, risk of death was constant at 22%/year (68% confidence limits, 19%-25%/year).
Survival at 1, 3, 5, 7, and 10 years after surgery in matched patients was 56% versus 83%, 39% versus 70%, 24% versus 59%, 10% versus 49%, and 1.4% versus 38% for hemodialysis versus nonhemodialysis patients, respectively (Figures 2, B, and E3, B) . Cause of death was available for 52% (57 of 110) of matched patients; IE was listed as the cause in 10 hemodialysis patients and 5 nonhemodialysis patients.
Survival was similar for the 45 unmatched hemodialysis patients and the 99 matched hemodialysis patients (P ¼ .2, log-rank test) ( Figure E4 ).
Risk Factors for Mortality: Surgical Patients on Hemodialysis
Longer aortic clamp time was associated with higher early mortality after surgery in hemodialysis patients (Table 4) . Risk factors for later mortality were left main disease, lower grade of aortic valve regurgitation, arteriovenous graft for vascular access, preoperative pacemaker, and IE caused by unidentified microorganisms (Table 4 and Figure 3 ).
Reoperation: Surgical Patients
Eleven of the hemodialysis patients underwent valve reoperation during follow-up. Reoperation at 1, 3, 5, and 7 years in hemodialysis patients was 8%, 15%, 18%, and 20% ( Figure E5 ). After adjusting for competing risk of death, reoperation at these time points in hemodialysis patients was 3%, 7%, 13%, and 13%, respectively. Reoperation was similar for matched hemodialysis and nonhemodialysis patients at 1, 3, 5, and 7 years: 4% versus 5%, 11% versus 9%, 17% versus 14%, and 22% versus 18%, respectively (P >.9) ( Figure E6 ). After adjusting for competing risk of death, reoperation at these time points was 2%, 5%, 12%, and 12% for matched hemodialysis patients and 4%, 5%, 9%, and 18% for matched nonhemodialysis patients, respectively ( Figure E7 ).
Nonsurgically Treated Hemodialysis Patients
Of the 29 hemodialysis patients with IE treated nonsurgically, 24 had a surgical indication but were not operated on; 22 were deemed inoperable by consultant cardiac surgeons because of high surgical risk and other comorbidities, 1 refused surgery, and surgery was postponed for 1 pending resolution of other infectious issues. Of these 29 patients, 16 (55%) were male and 10 (34%) were black; mean age was 62 AE 9.7 years.
Eighteen patients (62%) had mitral valve involvement, 8 (28%) had aortic valve involvement, 2 (7.0%) had mitral and aortic valve involvement, and 1 (3.4%) had mitral, aortic, and tricuspid valve involvement. Seven patients (24%) had PVE. The causative agent was S aureus in 17 patients (59%), enterococcus in 6 (21%), coagulase-negative staphylococcus in 3 (10%), fungus in 1, Streptococcus viridans in 1, and other in 1.
Eleven patients (38%) died in the hospital. Survival was 30% at 1 year, 22% at 3 years, and 11% at 5 years. All patients with PVE had died by the end of follow-up. Two survivors never had an indication for surgery. Twenty of the 24 patients with a defined surgical indication died during follow-up; their survival was 28% at 1 year, 19% at 3 years, and 9.4% at 5 years.
Of the 4 patients alive at end of follow-up, 2 had an indication for surgery based on vegetation size and mobility only, but did not have any hemodynamic indication and were apparently cured on follow-up. The other 2 patients had a hemodynamic indication for surgery; 1 was deemed inoperable because of high risk, and the other was compensated and asymptomatic with good heart function. 
DISCUSSION Principal Findings
This series represents a contemporary surgical experience with IE in hemodialysis patients at a surgically aggressive tertiary center operating on more than 100 patients with IE per year, and it shows that despite poor long-term survival, surgery for IE should be considered for patients on hemodialysis. This is because intermediate-term survival, although worse in hemodialysis patients with IE treated surgically than in similar nonhemodialysis patients, is only slightly worse than that expected in the general hemodialysis population and substantially better than in hemodialysis patients with nonsurgically treated IE.
Findings in Context
Black patients constitute more than 35% of those on dialysis in the US. 17 In our study, 31% of surgically treated and 34% of nonsurgically treated chronic hemodialysis patients with IE were black. Although chronic kidney disease is more common in women than men, men are more likely to progress to end-stage renal disease. 18 Consequently, our study included more men than women in the hemodialysis group.
In agreement with the present study, others have reported S aureus as the leading cause of IE in hemodialysis patients, at approximately 50%. 4, 5, 19, 20 The presence of invasive and right-sided IE was similar in hemodialysis and nonhemodialysis patients, but native valve endocarditis was more common in the hemodialysis patients. This difference could be related to the increased exposure to pathogens from chronic hemodialysis access, leading to native valve endocarditis, as well as the small number of patients on dialysis who had undergone previous valve replacement.
Our hospital mortality after surgery compares favorably with the 24% mortality in dialysis patients reported in the Society of Thoracic Surgeons database. 3 Our institution's policy for managing patients with IE has shifted toward surgical intervention earlier in the course of disease, particularly in high-risk patients, such as those on hemodialysis. Early surgical intervention has been suggested by several other studies as well.
19-23
The overall long-term survival of patients on hemodialysis is poor. 9 In our study, survival after IE surgery was 15 percentage points lower in these patients, though still substantially better than the survival of hemodialysis patients with nonsurgically treated IE. Dohmen and colleagues 7 reported 0% survival at approximately 5 years in dialysis patients undergoing surgery for IE.
Patients with renal failure are prone to earlier calcification of tissue-valve prostheses; however, in a study reported by Leither and colleagues, 6 this did not translate into a survival advantage for mechanical valves. In dialysis patients without IE at our center, prosthetic valverelated complications are similar for both mechanical and bioprosthetic valves, which we attribute to the competing risk of mortality. 24 Survival after surgery in hemodialysis patients depends on the timing of surgery, execution of an expeditious successful operation, and good postoperative management. Thus, in general, we prefer tissue valves for patients with IE to reduce the need for anticoagulation and thus simplify postoperative management and reduce the risk of hemorrhagic conversion of ischemic stroke and intracerebral bleeding. Mechanical valves are still considered for younger and healthier patients, however.
In this study, IE context (native or prosthetic) was not a risk factor for mortality, in agreement with our most recent study of patients with left-sided IE. 10 Although other studies have reported worse outcomes with S aureus IE, 5, 11 it was not associated with higher time-related mortality in the present study. The duration of cardiopulmonary bypass was a risk factor for worse early mortality. Longer cardiopulmonary bypass time is a surrogate for more advanced pathology, which requires more time for complete debridement. Mitral annulus calcification also adds to the difficulty, time, and risk of surgery. Dialysis patients with an arteriovenous fistula for vascular access are considered at lower risk for infection compared with patients with a catheter or arteriovenous graft.
In this study, nearly one-half of the hemodialysis patients had arteriovenous fistulae for hemodialysis access, followed by catheters and arteriovenous grafts. The use of catheters for dialysis access has been associated with a greater risk of all-cause or infection-related mortality compared with arteriovenous grafts or fistulae 25 ; surprisingly, in this study, the few arteriovenous grafts were associated with a greater risk of mortality compared with arteriovenous fistulae or catheter access. The association of a lower grade of aortic valve regurgitation with a higher risk of death is a surrogate for mitral valve IE, which continues to be associated with a poorer prognosis for our patients undergoing surgery for IE regardless of whether they are on hemodialysis. 10 The prevalence of reoperation was similar for hemodialysis and nonhemodialysis patients, yet death from IE was more common in the hemodialysis patients. A possible explanation for this finding is that the hemodialysis patients were more often deemed inoperable when IE recurred.
Hemodialysis patients with nonsurgically treated IE represent a small but important subgroup of our study. Although these patients were either deemed inoperable or did not have a surgical indication and thus are not directly comparable to those undergoing surgery, they still provide a reference population in support of the value of surgical treatment for IE in hemodialysis patients.
Study Strengths and Limitations
Although this study is a single-center experience of 144 surgically treated IE patients on hemodialysis with follow-up data up to 12 years, it may be the largest series of its kind reported to date supporting surgical intervention in this high-risk population. It is an observational study, in which referral and selection bias may affect findings. For risk-adjusted comparison, we used propensity-score methods with 58 variables to identify matched pairs of hemodialysis and nonhemodialysis patients; however, important patient factors that might have affected outcomes but were not recorded or included in the propensity model may have biased our findings.
Hemodialysis patients who did not undergo surgery do not represent the natural history of IE, and many early deaths occurred among those not deemed surgical candidates. Duke criteria were incompletely documented in some of these patients. Moreover, because this is a singlecenter experience, our findings might not be generalizable. Time on hemodialysis is an important risk factor for mortality, 9 but we were unable to extract this information from medical records.
CONCLUSIONS
Intermediate-term survival after surgery for IE in hemodialysis patients was substantially worse than that in non-hemodialysis patients, but only slightly worse than that in the general hemodialysis population and substantially better than that in hemodialysis patients with IE treated nonsurgically. We thus conclude that it remains worthwhile to operate for IE in patients on hemodialysis.
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Discussion
Dr F. Sellke (Providence, RI). I would like to congratulate the authors on their presentation regarding the outcomes of patients undergoing surgery for infective endocarditis in the dialysis population. Endocarditis is an increasing clinical problem worldwide and especially in the United States, where the use of intravenous narcotics is becoming near epidemic. The dialysis population is another group of patients with an increasing incidence who are prone to infective endocarditis due to their diminished immune system function and the repeated instrumentation of their vasculature.
In contrast to those patients abusing intravenous drugs, the dialysis population does not choose, in large part, to develop renal failure and to be dialyzed. Thus, it would be unethical to withhold surgical therapy in this group of patients regardless of the added benefit these patients may derive from surgery.
The study demonstrates that patients suffering from infective endocarditis and undergoing surgery have a poorer
prognosis, but what is remarkable to me is that the general hemodialysis population has nearly as poor a prognosis. By the very nature of the study, the groups cannot be well controlled with regard to clinical variables. However, the authors have done a nice job attempting to make this a balanced, real-world comparison between the surgical results for endocarditis between dialysis and nondialysis patients.
I have several questions. First, we are seeing a large increase in the number of patients with infective endocarditis due to intravenous drug abuse. However, I did not see any mention of this in the paper. If one excludes these patients abusing drugs, do the results change? I would suspect that the outcomes in the nonhemodialysis population would actually improve versus the hemodialysis patient suffering from endocarditis.
Dr Raza. Thank you for your comments, Dr Sellke. We didn't specifically look into that, but it is well worth investigating. [These data were later abstracted. Five HD patients were active intravenous drug users. One of these patients was in the matched HD group. In the matched non-HD group, 4 patients were active intravenous drug users. Given these small numbers, we do not have enough data for any meaningful comparisons.] Dr Sellke. Secondly, it is somewhat surprising that the incidence of prosthetic valve endocarditis was present in 19% of hemodialysis patients versus 36% of nonhemodialysis patients. Do you have an explanation for this and were the outcomes different between these 2 patient groups?
Dr Raza. There could be several reasons for this. First, hemodialysis patients are sicker than nonhemodialysis patients and have indwelling vascular access; thus, they are at higher risk in general of getting native valve endocarditis. Second, compared with nonhemodialysis patients, our guess is that fewer chronic hemodialysis patients have a history of cardiac surgery and an artificial valve in place.
Native or prosthetic valve endocarditis was not identified as a risk factor for mortality after surgery. This is in agreement with previous findings that in patients with endocarditis, long-term survival is similar whether we operate on a prosthetic valve or a native valve.
Dr Sellke. Interestingly, the duration of cardiopulmonary bypass was associated with a poorer short-term prognosis. Can you elaborate on why this may be the case? Is it due to just the inflammation due to bypass, the extent of structural deterioration and the need for debridement and reconstruction, or other factors?
Dr Raza. Longer cardiopulmonary bypass indicates a more challenging case with more aggressive disease, which requires more time for complete debridement.
Dr Sellke. Finally, there is no mention of the surgical treatment these patients received, whether it was debridement and prosthetic valve replacement, homograft replacement, or mainly, in the case of tricuspid and mitral valve endocarditis, valve repair. Chris Feindl, in the last issue of the Journal of Thoracic and Cardiovascular Surgery, said it was more important what you take out than what you put in which determined the recurrence of the endocarditis. What is your approach to this? Dr Raza. Our approach is complete debridement of all infected tissue and foreign material, followed by generous irrigation. If we have to reconstruct the aortic root, the choice of material is an allograft. However, if for the aortic valve the annulus is preserved, then the choice of prosthesis is basically the same as for any other patient. We prefer tissue valves, because anticoagulation is an additional issue in these patients, and anticipated patient longevity is not that good.
For mitral valves, we prefer repair versus replacement. If replacement is done, it is done with chordal sparing.
Dr Sellke. Again, I would like to thank you for a very timely and interesting study.
Dr Raza. Thank you very much.
Dr R. Damiano (St. Louis, MO). Congratulations on a very nice study and very beautiful presentation. I was just going to elaborate a little bit on Dr Sellke's last question. I was very impressed with the dramatically poor survival in these patients, and I just wonder if you could elaborate if that has had an impact on your choice of valve prosthesis since most are dead in 5 years?
I also would like you to comment on the fact that generally it is in the hemodialysis patients that bioprosthetic valves have an incredibly short life expectancy because of the often profound and early calcification. 
